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Schistosomiasis, a neglected tropical disease of poverty ranks second among the most
widespread parasitic disease in various nations in sub-Saharan Africa. Neglected tropical
diseases are causes of about 534,000 deaths annually in sub-Saharan Africa and an estimated
57  million disability-adjusted life-years are lost annually due to the neglected tropical dis-
eases.  The neglected tropical diseases exert great health, social and ﬁnancial burden on
economies of households and governments. Schistosomiasis has profound negative effects
on  child development, outcome of pregnancy, and agricultural productivity, thus a key rea-
son  why the “bottom 500 million” inhabitants of sub-Saharan Africa continue to live in
poverty. In 2008, 17.5 million people were treated globally for schistosomiasis, 11.7 million
of  those treated were from sub-Saharan Africa. This enervating disease has been success-
fully eradicated in Japan, as well as in Tunisia. Morocco and some Caribbean Island countries
have  made signiﬁcant progress on control and management of this disease. Brazil, China
and Egypt are taking steps towards elimination of the disease, while most sub-Saharan
countries are still groaning under the burden of the disease. Various factors are responsible
for the continuous and persistent transmission of schistosomiasis in sub-Saharan Africa.
These include climatic changes and global warming, proximity to water bodies, irrigation
and dam construction as well as socio-economic factors such as occupational activities and
poverty. The morbidity and mortality caused by this disease cannot be overemphasized.
This review is an exposition of human schistosomiasis as it affects the inhabitants of vari-
ous  communities in sub-Sahara African countries. It is hoped this will bring a re-awakeningtowards efforts to combat this impoverishing disease in terms of vaccines development,
alternative drug design, as well as new point-of-care diagnostics.
© 2015 Elsevier Editora Ltda. All rights reserved.
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ntroduction
uman schistosomiasis otherwise called bilharzia, is a fresh-
ater snail transmitted intravascular debilitating disease
esulting from infection by the parasitic dimorphic Schisto-
oma trematode worms, which lives in the bloodstream of
umans.1,2 The World Health Organization (WHO) regards the
isease as a neglected tropical disease, with an estimated
32 million persons being vulnerable to infection worldwide
n renowned transmission areas.3 Steinmann and co-workers
ocumented that over 200 million individuals from Africa,
sia, and South America are infected with this disease.1 The
HO further estimated that schistosome infections and geo-
elminths accounts for over 40% of the world tropical disease
urden with the exclusion of malaria.4 Humans get infected
ith this disease when they make contact with water con-
aminated with the skin-penetrating cercariae. Prevalence of
chistosomiasis, at present, is still high in sub-Saharan Africa.
n 2008, 17.5 million people were treated globally for schisto-
omiasis, 11.7 million of those from sub-Saharan Africa only.3
pproximately 120 million individuals in sub-Saharan Africa
ave schistosomiasis-related symptoms while about 20 mil-
ion undergo hardship as a result of chronic presentations of
he disease.5
Schistosomiasis has been successfully eliminated in Japan
nd Tunisia. Morocco and some Caribbean Islands countries
ave made signiﬁcant progress on controlling the disease
hile Brazil, China, and Egypt are taking steps towards elim-
nation of the disease.6 Schistosomiasis is more  rampant
n poor rural communities especially places where ﬁshing
nd agricultural activities are dominant. Domestic activities
uch as washing clothes and fetching water in infected water
xpose women and children to infection. Recreational activ-
ties like swimming and poor hygiene also make children
ulnerable to schistosomiasis.3 Humans are usually infected
y ﬁve species of schistosomes, namely Schistosoma mansoni,
chistosoma haematobium, Schisosoma japonicum, Schistosoma
ekongi, and Schistosoma intercalatum, but the main burden
f disease in sub-Saharan Africa is usually attributed to
wo species, namely, S. mansoni and S. haematobium and are
eferred to as the major human schistosomes.6
Biomphalaria snails are responsible for the transmission
f S. mansoni which is the source of hepatic and intestinal
chistosomiasis in places like the Arabian countries, South
merica, and Africa. Bulinus snails transmit S. haematobium
hich is the chief cause of urinary schistosomiasis in Africa
nd in the Arab world.2 The Biomphalaria snails comprise many
pecies including B. alexandrina, B. sudanica, B. pfeifferi, and B.
oanomphala, while the genus Bulinus comprises the follow-
ng species; B. tropicus, B. globosus, B. truncatus, B. forskalli, and
. africanus.7 Schistosoma japonicum is spread by the freshwa-
er snail Oncomelania and it is responsible for intestinal and
epatosplenic schistosomal infections in Indonesia, Peoples
epublic of China, and the Phillipines. It is a zoonotic para-
ite infecting animals including pigs, dogs, cattle, and rodents.
ome other species of schistosome are parasites of different
nimals, but occasionally infect humans. S. mansoni can also
e found in primates and rodents but the main host are human
eings.25;1 9(2):196–205 197
Matured schistosomes are usually greyish or white worms
with a length of 7–20 mm,  having a cylindrical shape with
two ending suckers, a blind digestive tract, a complex tegu-
ment, and reproductive organs. A distinguishing feature in
this trematode compared with other trematodes is its exist-
ence in two sexes. The male has a gyneaphoric channel or
a groove, wherein it grips the female which is usually longer
and thinner. The male and female schistosomes live as perma-
nently embraced couples in the perivesical venous plexus (in S.
haematobium) or in the mesentric venous plexus (in S. mansoni
and S. japonicum species). The schistosomes get nourishment
from the host blood and globulins by means of anaerobic gly-
colysis and excrete the waste back into the body of the hosts.2
A female schistosome has the capacity to produce hundreds
of eggs per day as discovered in the African species, and about
thousands of eggs per day in the oriental species. The individ-
ual ovum is home to miracidium larva with cilia that produce
proteolytic enzymes which aid the eggs to move either towards
the lumen of the bladder or towards the host intestine.2
Subsequently, the parasites eggs are released into the fae-
ces or urine where they remain alive for about seven days.
When they get into freshwater, the miracidium is released
from the egg. With the aid of chemical stimuli and light, the
miracidium seeks the freshwater snail which is its intermedi-
ate host. On locating the snail, the miracidium penetrates it
and undergoes asexual reproduction to produce multicellular
sporocytes which develop to cercarial larvae having embry-
onic suckers as well as a two-branched tail.2 After 4–6 weeks
of infecting the snail, the cercariae leave the snail and gyrates
around for about 72 h looking out for the skin of a prospective
host. Once released from the snail the cercariae are instigated
by light mainly during the day time. On locating a human
host skin, the cercariae burrow into it, migrate into the blood
through the liver and lungs and undergo transformation into
schistosomula also called young worms.2
The schistosomula mature within 4–6 weeks inside the por-
tal vein, mate, and migrate to their destination, which is either
the perivesicular or mesenteric venous plexus, to start the
cycle again (Fig. 1). A single infected snail has the potential of
shedding thousands of cercariae daily for many  months. An
adult schistosome has an average lifespan of between three
to ﬁve years, but it can as well live for 30 years. A single schis-
tosome pair has a theoretical reproduction potential of up to
600 billion schistosomes.2 The intermediate freshwater snail
inhabit calm or slowly moving freshwater lakes, rivers, ponds,
or streams. The rate of infection in human increases with the
duration of time spent in contaminated water.8 Microscopic
examination of stools and urine is the gold-standard for detec-
tion (diagnosis) of schistosomal infection. The schistosome
eggs are easily seen and identiﬁed on microscopy due to its
peculiar size and shape, and possession of a lateral or terminal
spine.8
Schistosomiasis:  a  neglected  tropical  disease  of
povertyNeglected tropical diseases (NTDs) are generally referred to
as a collection of chronic, disabling, and physically disﬁguring
infectious diseases that are found mostly among poor rural
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Fig. 1 – Life cycle of Schistosoma 1. Deﬁnitive host, 2. Schistosome eggs released in urine or faeces of deﬁnitive host, 3.
Free-swimming miracidia from eggs, 4. Intermediate host, 5. Cercaria (penetrates skin, loses its tail and transforms into
schistosomulum), 6. Paired adult worm (schistosomulum migrates to the hepatic portal system; adult worms mature in
pairs in the veins surrounding the bladder, intestines or liver. They produced eggs, the majority of which are eliminated in
gs hurine or faeces of deﬁnitive host to the environment. The eg
dwellers and some urban population. Studies have revealed
that the NTDs are more  prominent in sub-Saharan African
communities. NTDs have profound negative effects on chil-
dren development, outcome of pregnancy, and agricultural
productivity, thus a key reason why the “bottom 500 million”
inhabitants of sub-Saharan Africa continue to be in poverty.
This led to the concern for elimination of the NTDs as a major
element of the Millennium Development Goals MDGs.9
More  than 17 diseases are referred to as NTDs but seven of
them have attracted more  attention due to their high preva-
lence and resistance to control worldwide.10 NTDs poses great
health as well as economic challenges for the poor dwellers
of Africa, Latin America as well as Asia. These diseases are
the cause of about 534,000 deaths annually; an estimated 57
million disability-adjusted life-years (DALYs) are lost annually
due to the NTDs. These neglected tropical diseases put great
health, social, and ﬁnancial burden on economies of house-
holds and governments.11
Schistosomiasis is the second most common NTDs after
hookworm in Sub-Saharan Africa. Children and young adults
bear most of the burden resulting from this disease in Africa.
Sub-Saharan Africa accounts for 93% (192 million) of the world
estimated 207 million cases of schistosomiasis. The highest
prevalence of this infection is seen in Nigeria (29 million),
which is closely followed by United Republic of Tanzania (19
million), Ghana, and Democratic Republic of Congo (15 million)atch liberating miracidia to restart the life cycle.71
making up the top ﬁve countries in Africa with schistosomal
infection (Fig. 2). However, underestimation of the true preva-
lence of schistosomiasis has been reported; it is proposed that
the prevalence of schistosomal-related diseases may be more
than 400–600 million globally.12
Prevalence  of  schistosomiasis  in  some  sub-Saharan  Africa
countries
S. mansoni is the chief cause of clinical abnormalities such
as hepatomegaly, splenomegaly, and periportal ﬁbrosis in
various sub-Saharan Africa countries. A study in northern
Ethiopia in Alamata district revealed an alarming 73.9%
prevalence of schistosomal infection, with presentation of
3.7% hepatomegaly, 7.4% splenomegaly, and 12.3% peripor-
tal ﬁbrosis.13 A cross-sectional study carried out among 362
school age children in Machakos district in Kenya showed
varying intensities of S. mansoni infections and its associa-
tion with hepatomegaly. It was observed that infected children
exhibited stunted growth and wasted muscles compared with
children without infection.14 Cases of appendicitis-related to
schistosomal infections have been reported in various stud-
ies. Schistosomal appendicitis caused by S. mansoni infection
is an unusual complication in endemic communities with
0.02–6.3% prevalence, which represents 28.6% of severe appen-
dicitis cases in such endemic regions.15
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Schistosomiasis burden in subSaharan Africa
Ghana 15
Nigeria 29
Tanzania 19
Mozambique 13
Congo, DRC 15
N
Legend
Country_Prevalence
Prevalence / SubSaharan_total
0.0069
Prevalence
SubSaharan_total
Africa_countries
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Fig. 2 – Map  of Africa showing ranking of estimated schistosomiasis burden in sub-Saharan African (SSA) countries.
Schistosomiasis prevalence in SSA is documented to be 192 million, which is 93% of the total global prevalence of the
disease. A total of 29 million people are infected by this disease in Nigeria, 19 million in Tanzania, 15 million each in
Democratic Republic of Congo and Ghana, while Mozambique with 13 million people completes the top ﬁve countries with
the highest prevalence in SSA. This prevalence ﬁgures by country are represented by a pie chart as a ratio of the total
disease burden in SSA using a normalization ﬁgure of 0.0069. The prevalence ﬁgures are taken from Hotez and Kamath,9
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A study carried out in Nigeria reported that 2.3% of over
000 cases of appendicitis had schistosome eggs discovered
n histological sections, with 56% of the cases attributable to
. mansoni, 26.0% to S. haematobium, and 19.0% to coinfection
y both species.16 In another study, 4.2% of appendicitis cases
ere classiﬁed as schistosomiasis of the appendix.17 Schisto-
omiasis due to S. mansoni is on top of the list of the causes of
ulmonary hypertension worldwide, especially in areas where
chistoasomiasis is endemic.18
A survey of school children aged 5–19 years in Mbita and
ome Islands close to Lake Victoria in Kenya revealed that
he communities were highly endemic for S. mansoni infection
ith prevalence as high as 60.5%.19 Another survey cover-
ng the inhabitants of Lake Rweru in Rwanda indicated that
1.1% of the population screened had intestinal schistosomia-
is. This suggests a likely high prevalence of schistosomiasis
n the communities evaluated. Out of three communities vis-
ted, one community had a single case of infection, which
ould be attributed to the presence of piped water in that
ommmunity.20
A study carried out in Yewa North Local Government of
gun State, Nigeria buttressed the fact that schistosomiasisare.
exists among pregnant women. The study population
consisted of pregnant women of age range 15–42 years. A
prevalence of 20.8% of S. haematobium infection was observed,
with the younger pregnant women at greater risk of the infec-
tion, which is in consonance with a previous report from
Tanzania. It was also observed that the prevalence recorded
within pregnant mothers in Yewa North was obviously lower
compared with earlier reports from similar population groups
due to a taboo in that part of the country restricting pregnant
women from visiting natural water bodies.21
A cross-sectional study of school children aged 8–17 years
in Sengerema District, Nyamatongo ward of North-West Tan-
zania, revealed an alarming prevalence of 64.3% S. mansoni
infection. This prevalence was remarkably high in spite of
previous control efforts in the ward such as mass drug
administration.22 An investigative study of in-school and not-
in-school children aged 6–15 years living in communities along
the Tono Irrigation Canal in North Ghana revealed a preva-
lence of 33.2% of S. haematobium infection and a 19.8% for S.
mansoni. An overall schistosomiasis prevalence of 47.7% was
reported. It was also observed that there was higher infection
rate in male children compared to their female counterparts,
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which might be due to longer period of contact with contam-
inated water.23
A study consisting of adult male and female subjects resid-
ing in the Volta Basin of Ghana revealed a 46.5% prevalence
of urinary schiatosomiasis; this report is a good indication
that schistosomal infection prevalence is not transient among
adults.24 An investigative study carried out in Zenu, a sur-
burb community of the capital city of Ghana, revealed a
prevalence of 30.7% of urinary schistosomiasis among the
study population of school children aged 3–16 years. Demo-
graphic analysis showed that the proximity of households
to a dam was associated with the prevalence observed
among the children.25 A high prevalence (57.6%) of urinary
schistosomiasis and elevated intensity of S. haematobium
infection (185 eggs/ml) was also reported among school-
age children in Niakhar District, Senegal. This endemicity
could be attributed to the inhabitants’ great dependence on
backwater and ponds for various domestic and recreational
activities.26
The report of a pilot study in 2010, in the Eastern Cape
Province of South Africa, with school-age students revealed
an alarming prevalence of 73.3%. The authors observed that
due to the study population size being small, there was need
for further study to determine the extent of schistosomia-
sis in the area.27 A nation-wide survey of the prevalence of
schistosomal infections and soil helminths in school chil-
dren from Mozambique reported a prevalence of 47.0% S.
haematobium infection and 1.0% S. mansoni infection. Fur-
ther observation from this study showed that infection
increases with age, with the age group 10–14 years having
the highest prevalence of S. haematobium infection. It was
also observed that across the districts, male children had
higher prevalence compared to their female counterparts. The
high prevalence of schistosomiasis was attributed to inad-
equate water supply in the districts, poor sanitation, and
a low level of socioeconomic development in most parts of
Mozambique.28
A cross-sectional study carried out in Zarima town, north-
west Ethiopia among 319 elementary school children revealed
a prevalence of 37.9% S. mansoni infection. The researchers
observed an increased prevalence compared with previous
studies in the area despite school deworming programmes.
A study done at Barombi Kotto focus, South West Camer-
oun, revealed an alarming 69.17% prevalence of S. haematobium
infection conﬁrming high endemicity in the area. It was noted
that most lakes in the area were habitats for the B. globo-
sus intermediate host required for disease transmission.29
Added to this, another study carried out in Agboville, Cote
d’Ivoire among school-aged children showed a very high
prevalence of 85.3% and 53.8% for S. haematobium and S. man-
soni respectively.30
Schistosomal  morbidity  and  mortality  in
sub-Saharan  AfricaThe signiﬁcance of morbidity and mortality resulting from
helminthic infections including schistosomiasis has been
grossly underestimated in most developing countries.12
School-aged children, teenagers, women and young adults 1 5;1  9(2):196–205
are mostly hit with the morbidity and mortality associated
with schistosomiais.31 Population studies of schistosoma-
infected children revealed that schistosomiasis can cause
growth retardation, fatigue, weakness, impairment of mem-
ory and cognitive reasoning, and increased risk of anaemia,
leading to poor academic performance, thus limiting the
potential of infected children.8 These negative outcomes
in children add to the socioeconomic burden of the
society.11
Though schistosomiasis is rarely fatal, it causes long term
morbidity such as anaemia which results from bleeding from
the urinary and intestinal tracts due to worm invasion and
movements; iron deﬁciency is also an outcome of the disease
sequel to nutritional impairment such as nutrient malab-
sorption and digestive disorder like diarrhoea.32 A study in
Daekena, in the Republic of Niger an area endemic for urinary
schistosomiasis, revealed 41.7% of the 174 school children hav-
ing iron deﬁciency while 57.7% exhibited anaemia related to
iron deﬁciency.33 A longitudinal study in Burkina Faso among
1727 Burkinabe children aged 6–17 years revealed a dramatic
increase in haemoglobin concentration following chemother-
apy of S. haematobium compared with baseline concentration
a year earlier.34
Clinical observation and autopsy strongly indicate that
people, speciﬁcally elderly patients, die as a result of
schistosomal-induced kidney damage.2 Urogenital schistoso-
miasis is a key predisposing agent for Human Immunodeﬁ-
ciency Virus (HIV) transmission. Urogenital schistosomiasis
in HIV-infected women increases the ease of transmission
to male sexual partners, as well as transmission from an
HIV-infected male to his sexual partner. It also hastens
the progression of the disease in people already infected
with the virus by increasing the plasma concentration of
the HIV RNA (viral load).35 A study among Zimbabwean
women showed that women with S. haematobium eggs in
their pap smear had a risk three times higher of having
HIV.36
Studies on animal models and human subjects have estab-
lished adverse consequences of schistosomiasis on pregnancy
outcomes. S. haematobium infection has been linked to pla-
cental inﬂammation, leading to poor birth-outcomes as a
result of placental incompetency. Heavy S. mansoni infec-
tion has also been linked to higher risk of anaemia that
might subsequently lead to maternal mortality or low birth
weight (LBW) babies. The anaemia may be due to urinary iron
loss and faecal waste. Proinﬂammatory cytokines resulting
from schistosomiasis infection leads to anorexia or loss of
appetite of pregnant women which might ultimately result
in reduced maternal weight gain and thus lead to a LBW
baby.37 An observational study in Tanzania showed that there
was a high prevalence of S. mansoni infection among the
pregnant women and the high intensity of infection exposes
the women to a higher risk of anaemia during pregnancy.38
Another study in Tanzania linked the delivery of LBW babies
to infection with parasitic diseases including schistosomia-
sis during pregnancy.39 The study has shown an elevated
progression of liver ﬁbrosis in people co-infected with sch-
istosomiasis and hepatitis C virus in comparison with cases
of single infections, which ultimately led to advanced liver
disease.40
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actors  determining  the  continuous
ransmission  of  schistosomiasis  in
ub-Saharan  Africa
he continuous transmission of schistosomiasis in sub-
aharan Africa is attributable to various environmental and
ocio-economic factors such as:
limatic  changes
here is an established link between climatic changes and
nfectious disease transmission. Schistosomiasis is a typical
xample of diseases whose local infection and geographi-
al expansion is inﬂuenced by climatic changes and global
arming.41 Mangal and co-workers showed that a rise in
mbient temperature from 20 ◦C to 30 ◦C will lead to over ten-
old increase in the mean burden of S. mansoni infection in
ndemic areas. Nonetheless, at temperatures above 30 ◦C a
ecrease in the disease burden was observed, probably due
o higher death rate of the intermediate snail host. They
bserved that although an increase in disease burden leads
o increased morbidity and mortality, there might be a negli-
ible increase in prevalence of the disease.17 Rainfall patterns
lso have an effect on the transmission of schistosomiasis; in
enegal, the snail specie Biomphalaria pfeifferi is responsible for
. mansoni transmission during the raining season, while dur-
ng the dry season S. haematobium infection is transmitted by
ilunus globosus.42
roximity  to  water  sources
he schistosome parasite requires an avenue wherein there is
irect contact between the molluscan intermediate snail and
he ﬁnal human host for transmission of schistosomiasis to
ake place.43 An estimated 76% of the sub-Saharan popula-
ion live close to various open water bodies which are infested
ith the intermediate snail host necessary for the transmis-
ion of the disease.1 Various studies have established a direct
ssociation between the intensity of the disease and proxim-
ty of infected individuals to natural water sources such as
akes, rivers, and ponds.44,45 A study carried out in Blantryre
istrict in Malawi, showed that children whose school were
loser to open water bodies had increased risk of infection,44
 ﬁnding in consonance with that reported by Clennon and
o-workers.45
an-made  ecological  changes
cological changes due to man-made construction of
rrigation schemes, reservoirs and dams for agricultural pur-
oses and electricity generation are also responsible for
ontinued transmission of schistosomiasis in some in sub-
aharan African countries.46 Construction of dams led to
emarkable increase in cases of urinary schistosomiasis as
xperienced in some sub-Saharan Africa countries such as
4enegal, Cote d’Ivoire, Ghana, Mali, Namibia, and Cameroun.
teinmann and co-workers estimated that 13.6% (106 mil-
ion) of people vulnerable to schistosomiasis reside close to
rrigation schemes and large dam reservoirs.15;1 9(2):196–205 201
Socio-economic  factors
Socio-economic factors inﬂuencing the continuous transmis-
sion of the debilitating disease in sub-Saharan countries
include poverty occupational activities, poor sanitation and
hygiene, and non-availability of potable water for domestic
use.2 A World Bank analysis conﬁrmed that the majority of the
sub-Saharan population survive on between US$ 1.25–2 per
day.9 King postulated a vicious cycle between poverty and sch-
istosomiasis. He explained that poverty compels an individual
to utilizing contaminated water sources for his domestic activ-
ities therefore getting infected with the disease, on getting
sick due to the infection, he becomes unable to engage in
activities to earn his livelihood and thus, poverty persists.12
Ugbomoiko and co-workers established the link between sch-
istosomiasis and poverty in their cross-sectional study in two
peri-urban communities in Osun State, Nigeria. An alarming
62% prevalence was recorded among 1023 individuals under
study.47
An analysis by Esrey and co-workers reported on the role of
improved water supply and hygiene on disease transmission
and incidence. They concluded that availability of safe water
and sanitation are necessary for reducing the incidence and
prevalence of schistosomiasis and some other water related
diseases.48 Many inhabitants of sub-Saharan countries have
limited access to potable water for domestic use, leaving them
with the option of using natural water bodies such as lakes,
rivers, ponds, and other water sources contaminated with
developmental stages of the schistosome parasite. A study
carried out in northern Nigeria showed the link between safe
water and intensity of urinary schistosomiasis. A higher rate
of infection (88.57%) was recorded in a community that only
had a pond as source of water for domestic use in comparison
with 0.59% in a neighbouring community with borehole.49
Occupational activities such as ﬁshing and farming are
also risk factors for transmission of the disease. Contact with
infected water is a vital factor in transmission of infection;
women and children get exposed to infection during activities
such as laundry, plate washing, water fetching for domestic
use and bathing. Recreational activities such as swimming and
diving also expose an individual to infection.3
Chemotherapy  for  schistosomiasis  and
associated  fallout
Several drugs have been used in the treatment of Schistosoma
infection, and notable among them are oxamniquine, metri-
fonate, artemisinin derivatives, and praziquantel. Artemisinin
is an antimalarial, which has been shown to have anti-
schistosomal properties, with the best outcomes with
artesunate and artemether. These drugs have the capacity to
kill juvenile worms of both S. mansoni and S. japonicum.  Tri-
als done in China and Cote d’Ivoire established the efﬁcacy of
artemisinin derivatives. However, there is widespread concern
on the use of these drugs in areas where malaria is endemic
50due to fear of raising Plasmodium resistance.
Praziquantel, a pyrazinoisoquinoline derivative has been
shown in randomized controlled trials to be a very safe
oral drug for the treatment of schistosomiasis caused by the
i s . 2 0202  b r a z j i n f e c t d 
various schistosome species.49 This drug is made of a white
crystalline bitter tasting compound which is stable in normal
storage condition and insoluble in water. Commercially, the
drug is available as a racemate mixture with equal ‘levo’ and
‘dextro’ isomers. The ‘levo’ part has schistosomicidal activity
in vivo and in vitro. It is mainly available as 600 mg  crystalline
tablets, but the generally recommended dosage is 40 mg/kg
body weight in a single dose. A 600 mg/5 ml  syrup is also avail-
able for small children.51 Praziquantel is still the best drug
for combating infections from all ﬁve species of schistosomes
afﬂicting humans, with a cure rate of 60–90% in various epi-
demiological settings.52
Millions of people are given the drug yearly in sub-Saharan
African nations, courtesy of various mass chemotherapy
control programmes, especially under the Bill and Mellinda
Gates Foundation sponsored Schistosomiasis Control Initia-
tive (SCI).53 In the year 2002, WHO  endorsed the drug safety for
treating pregnant women as well as lactating mothers. How-
ever, 100% cure rates have scarcely been recorded in endemic
areas.54 Praziquantel acts within an hour of oral ingestion
but its actual mechanism of action on the adult worm is not
yet known. Laboratory studies have revealed that the drug
causes contraction of tegumental vacuoles making the worm
to disengage from the wall of the veins and die. The calcium
ion channel of the schistosome worm has been indirectly
established as the molecular target of the drug.8 One of the
hypotheses of the mode of action of this drug states that it
inserts itself into the parasites membrane and produces lipid
phase transition thus destabilizing the membrane.52
Praziquantel negative effects are very mild and these
include nausea, vomitting, abdominal pain, malaise, and in
serious infections, intense colic and bloody diarrhoea soon
after treatment, which may be attributed to worm mass move-
ment and antigen release.2 Praziquantel does not have effect
on young worms both in vivo and in vitro. This signiﬁcant short-
coming is responsible for poor cure rate as well as treatment
failure reported in some studies, especially in areas where
transmission rate is very high. To overcome this, two courses
of drug administration has been advocated which gave a bet-
ter cure rate.51 Extensive and intensive usage of the drug gave
rise to concerns on the emergence of drug-resistant mutants
of the schistosomal parasites and thus, the need for research
into evolvement of new anti-schistosomal drugs.8
Schistosomiasis  and  cancer
Studies in Africa and in the Middle East have been carried out
aiming at establishing the relationship between inﬂammation
resulting from schistosomiasis and squamous cell carcinoma
of the bladder.55 The International Agency for Cancer Research
in association with the World Health Organization categorized
S. haematobium infection as carcinogenic. S. mansoni and S.
japonicum are associated with cervical, liver, as well as colo-
rectal carcinomas.56 Deposition of parasite ova in the bladder
leads to intense inﬂammatory reactions that are linked to the
release of oxygen-derived free radicals, which aids the pro-
duction of carcinogenic N-nitrosamines, and thus malignant
transformation. N-nitrosamine formation has been linked
to chronic bacterial infection in the urinary bladder due to 1 5;1  9(2):196–205
schistosomal infections.57 Groeneveld and co-workers stated
in their work that eradication of schistosomiasis as well as a
timely detection of bladder cancer will give room for efﬁcient
management of squamous cell carcinoma of the bladder in
African patients.58
Combating  schistosomiasis  in  sub-Saharan
Africa
Preventive chemotherapeutic approach using praziquantel is
the most common strategy to control schistosomiasis. It actu-
ally leads to decreased schistosomal-related morbidity but
high disease re-occurrence and transmission of infection still
persisted. Hence, in order to support the beneﬁts of the drug, it
must be administered at regular intervals for limitless period
of time to prevent recurrency of morbidity.8 The WHO  reported
that as at 2010, 34.8 million people were treated with prazi-
quantel in 30 countries; the drug was made available through
yearly donation of 250 million tablets. The WHO  set the
goal of controlling schistosomiasis-associated morbidity in all
endemic countries by the year 2020. It aimed at eliminating the
disease in all endemic countries by the year 2025 and to inter-
rupt transmission of schistosomal infections in non-endemic
regions such as America, Europe, East Mediterrranean, South-
East Asia, as well as some selected African countries.53
Despite sub-Saharan Africa countries having the highest
burden of morbidity and mortality associated with the dis-
ease, limited efforts have been made in the control of the
disease until the introduction of Schistosomiasis Control Ini-
tiatives in 2002 (SCI).59 The SCI successfully instituted national
schistosomiasis control programmes in some sub-Saharan
nations like Zambia, Mali, Tanzania, Burkina Faso, Niger and
Uganda. However, these programmes were not successful due
to incomplete vertical mass drug distribution. The coverage
of the programme was ineffective, infants and preschool chil-
dren were not administered the drug.46 More  so, below 50.0%
of the high risk population were given the drug while indi-
viduals who were not infected with the disease received the
drug as the focus was on treating everyone without case ﬁnd-
ing. Thus, morbidity reduction was very low and cessation of
transmission very limited.60 Before 2013, over US$  150 mil-
lion have been exhausted on schistosomiasis and other NTDs
in sub-Saharan African nations, and by 2013, there was  an
increase after the United States of America announced a fresh
funding for a initiative for combating NTDs.61
Realistically, most sub-Saharan African countries cannot
afford the estimated 1.2 billion tablets of Praziquantel required
to treat 400 million individuals per annum for ﬁve years at
a total cost of US$ 100 million.62 Thus, schistosomiasis con-
trol in these countries cannot be achieved without foreign
donor fundings.60 Over the decades, the approach used in
sub-Saharan countries has aimed at reducing morbidity of
infection,46 however, there is dire need for sustainable strate-
gies geared towards transmission control and elimination of
this impoverishing disease. Vaccines are known to be vital
in disease control and eradication; this was evident in the
1978 eradication of small pox.63 There is a consensus among
researchers in the ﬁeld that effective control of transmission
and long term morbidity control can be achieved through the
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ntroduction of anti-schistosomal vaccines capable of building
uman immune responses to parasite invasion.61,64
mprovement  in  water  supply,  sanitation  and  hygiene
mproved sanitation and access to safe water supply are key
actors in schistosomiasis control and elimination.31 Advance-
ent in water supply and sanitation play a role in general
conomic development and growth of a country.65 Campbell
nd colleagues66 opined that there is need to progress from
mphasis on treatment of morbidity due to infection towards
eduction in exposure to infection through the implementa-
ion of Water, Sanitation and Hygiene (WASH) intervention
olicy. Many  authorities in sub-Saharan Africa are not ded-
cated to making available clean water sources for their
ommunities, and without accessibility to clean water, eradi-
ation of schistosomiasis in sub-Saharan Africa will continue
o be a mirage.
ducating  people  on  behavioural  changes
here is a need to educate people, both young and old on
he implication of voiding their bladder and faecal waste into
ater bodies. This behavioural change will go a long way
n reducing contamination of water sources and thus lead
o reduction in the rate of transmission of schistosomiasis
nd some other water-transmitted diseases. An intensiﬁed
ffort at educating people on the risk of schistosomal infection
nd transmission is necessary to assist in achieving posi-
ive behavioural changes regarding waste elimination and
ersonal exposure to open water sources.9 Inhabitants of
ndemic areas need to be encouraged to reduce water con-
act as much as possible in a bid to reduce schistosomiasis
ransmission.67
nail  control
hough not in use in sub-Saharan Africa, the use of mollus-
icides reduces snail population but rarely eliminates them.
his is because the snails recolonize their habitat after a
hile, so regular and long-term application of the chemical is
equired. Although, this control method was successfully used
o achieve eradication of this disease in Morocco and Japan, it
as also used in control programme strategies in Egypt and
hina. Toxicity of the chemical to ﬁsh as well as to other
ater-dwelling organisms is of great concern ecologically and
conomically. Alternatives to chemical-based molluscicides
nclude the use of plant-based derivatives (e.g. endod) and
iological control with snail competitors.31
dvances  in  schistosomal  vaccine  candidates
ub-Saharan African researchers need to be aggressively
nvolved in the ongoing search for alternative drugs or anti-
chistosomal vaccines to overcome the inherent challenges
osed by this neglected but destructive disease of poverty.
he foregoing are some advances in vaccine discovery. Vac-
ine candidates for schistosomal infections are in different
hases of development. Some vaccines are in pre-clinical5;1 9(2):196–205 203
trial phase while others are in phase one and two clinical
trials. Examples include fatty acid binding protein (FABP), Cal-
pain, Triose-phosphate isomerase, and Tetraspanins, GST, and
Paramyosin.6 The Calpain subunit called Sm-p80 has been
experimentally tested for its anti-fecundity and anti-infective
efﬁcacy. Experimental mice vaccinated with DNA plasmids
with Sm-p80 and interleukin-2 (IL-2) provided 59% protec-
tion, while vaccination using plasmid designed with Sm-p80
and interleukin-12 (IL-12) gave 45% protection. The study
indicated that Sm-p80 is a good vaccine candidate for sch-
istosomiasis and further advancement and optimization is
needed for human trials.68 Triose-phosphate isomerase (TPI)
and tetraspanins are another group of antigens with promis-
ing vaccine potential; trials have been done on buffalos to
determine the efﬁcacy levels of both vaccines on their own
and fused together with heat-shock protein 70 (Hsp70). The
vaccine constructs are SjCTP1-Hsp70 and SjC23-Hsp70; the
former was reported to be more  successful as it produced a
worm burden decrease of 51.2%, liver egg decrease of 61.5%,
faecal waste egg reduction of 52.1%, and 52.1% decrease in
hatching faecal miracidia.69
Pearson and colleagues70 also succeeded in producing a
chimeric vaccine named Sm-TSP-2. Their study indicated that
this vaccine antigen could be safely used against schistosome
adult worms and liver eggs as well as for the hookworm par-
asite. The 28 kDa GST recombinant protein (Sh28GST) from
S. haematobium has been experimentally tested regarding
safety, immunogenicity, as well as toxicity. The vaccine can-
didate molecule, paramyosin (rSj97) recombinant fraction
has also been discovered to give protection together with
immunogenicity in BALB/c mice. The full length recombinant
paramyosin protein elicited antibody responses in humans
with re-infection resistance.6 However, till the moment, sci-
entiﬁc hurdles and socioeconomic factors remain major
challenges towards successful transition of the above men-
tioned vaccine candidates into forms that could be used for
schistosomiasis intervention in sub-Saharan Africa and other
regions of the world.64
Conclusion
For many  decades human schistosomiasis has been of great
health concern globally and mostly in communities of sub-
Saharan Africa. The economic loss, disability and agony
caused by the various species of schistosomes cannot be
over-emphasized. Concerted efforts should be made towards
the elimination of this disease of poverty in all countries in
sub-Saharan Africa. The various authorities in sub-Saharan
countries should make provision of clean and safe water avail-
able for the citizens. There should be constant awareness
programmes to educate the population on the prominence of
sanitation and hygiene in achieving disease control and the
effect of schistosomiasis on the quality of life and general
well-being of people.
Most importantly, it is hoped that this review will
generate new interest among researchers in sub-Saharan
Africa towards further scientiﬁc discoveries to combat sch-
istosomiasis, in terms of alternative drugs to address
re-infection and resistance, vaccine discovery, formulation of
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point-of-care diagnostics, snail control, and other germane
discoveries that will serve as guide to voting-off schistosomia-
sis in sub-Saharan Africa and some other endemic regions of
the world.
Conﬂicts  of  interest
The authors declare no conﬂicts of interest.
Acknowledgements
The authors would like to thank Mr  Henok Solomon of the
Department of Earth Sciences, University of the Western Cape,
Bellville for the help received in generating the schistosomia-
sis burden in sub-Saharan Africa map.
 e  f  e  r  e  n  c  e  s
1. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J.
Schistosomiasis and water resources development:
systematic review, meta-analysis, and estimates of people at
risk.  Lancet Infect Dis. 2006;6:411–25.
2. Gryseels B, Polman K, Clerinx J, Kestens L. Human
schistosomiasis. Lancet. 2006;368:1106–18.
3. World Health Organization. WHO  schistosomiasis fact sheet;
2014. Available from:
http://www.who.int/mediacentre/factsheets/fs115/en
[accessed 10.04.14].
4. Olveda DU, Li Y, Olveda RM, et al. Bilharzia: pathology,
diagnosis, management and control. Trop Med Surg.
2013;1:135.
5. Chitsulo L, Engels D, Montresor A, Savioli L. The global status
of  schistosomiasis and its control. Acta Trop. 2000;77:41–51.
6. Utzinger J, Raso G, Brooker S, et al. Schistosomiasis and
neglected tropical diseases: towards integrated and
sustainable control and a word of caution. Parasitology.
2009;136:1859–74.
7. Ekpo UF, Oluwole AS, Abe EM, Etta HE, Olamiju F, Maﬁana CF.
Schistosomiasis in infants and pre-school children in
sub-Saharan Africa: implication for control. Parasitology.
2012;139:835–41.
8. Gray DJ, Ross AG, Li Y, McManus DP. Diagnosis and
management of schistosomiasis. Br Med J. 2011;342:d2651.
9. Hotez PJ, Kamath A. Neglected tropical diseases in
sub-Saharan Africa: review of their prevalence, distribution,
and disease burden. PLoS Negl Trop Dis. 2009;3:e412.
0. Deribe K, Meribo K, Gebre T, et al. The burden of neglected
tropical diseases in Ethiopia, and opportunities for integrated
control and elimination. Parasit Vectors. 2012;5:240.
1. Conteh L, Engels T, Molyneux D. Socioeconomic aspect of
neglected tropical diseases. Lancet. 2010;375:239–47.
2. King CH. Parasites and poverty: the case of schistosomiasis.
Acta Trop. 2010;113:95–104.
3. Abebe N, Erko B, Medhin G, Berhe N. Clinico-epidemiological
study of Schistosomiasis mansoni in Waja-Timuga, District of
Alamata, northern Ethiopia. Parasit Vectors. 2014;7:
158.
4. Corbett EL, Butterworth AE, Fulford AJC, Ouma JH, Sturrock
RF. Nutritional status of children with schistosomiasis
mansoni in two different areas of Machakos District, Kenya.
Trans R Soc Trop Med Hyg. 1992;86:266–73.
5. Elbaz T, Esmat T. Hepatic and intestinal schistosomiasis:
review. J Adv Res. 2013;4:445–52.
3 1 5;1  9(2):196–205
6. Badmos KB, Komolafe AO, Rotimi O. Schistosomiasis
presenting as acute appendicitis. E Afr Med J. 2007;83:528–32.
7. Gali BM, Nggada HA, Eni EU. Schistosomiasis of the appendix
in  Maiduguri. Trop Dr. 2006;36:162–3.
8. Lapa M, Dias B, Jardim C, et al. Cardiopulmonary
manifestations of hepatosplenic schistosomiasis. Circulation.
2009;119:1518–23.
9. Odiere MR, Rawago FO, Obok M, et al. High prevalence of
schistosomiasis in Mbita and its adjacent islands of Lake
Victoria, western Kenya. Parasit Vectors. 2012;5:278.
0. Ruberanziza E, Mupfasoni D, Karibushi B, et al. A recent
update of Schistomiasis mansoni endemicity around Lake
Rweru. Rwanda Med J. 2010;68:5–9.
1. Salawu OT, Odaibo AB. Schistosomiasis among pregnant
women in rural communities in Nigeria. Int J Gynaecol
Obstet. 2013;122:1–4.
2. Mazigo HD, Waihenya R, Mkoji GM,  et al. Intestinal
schistosomiasis: prevalence, knowledge, attitude and
practices among school children in an endemic area of North
Western Tanzania. J Rural Trop Public Health. 2010;9:53–60.
3. Anto F, Asoala V, Adjuik M, et al. Water contact activities and
prevalence of schistosomiasis infection among school-age
children in communities along an irrigation scheme in rural
Northern Ghana. J Bacteriol Parasitol. 2013;4:177.
4. Yirenya-Tawiah DR, Annang T, Otchere J, et al. Urinary
schistosomiasis among adults in the Volta Basin of Ghana:
prevalence, knowledge and practices. J Trop Med  Parasitol.
2013;34:1–16.
5. Tetteh-Quarcoo PB, Attah SK, Donkor ES, et al. Urinary
schistosomiasis in children – still a concern in part of the
Ghanaian capital city. Open J Med Microbiol. 2013;3:
151–8.
6. Senghor B, Diallo A, Sylla SN, et al. Prevalence and intensity of
urinary schistosomiasis among school children in the district
of  Niakhar, region of Fatick, Senegal. Parasit Vectors. 2014;7:
5.
7. Meents EF, Boyles TH. Schistosoma haematobium prevalence in
school children in the rural Eastern Cape Province South
Africa. S Afr J Epidemiol Infect. 2010;25:28–9.
8. Augusto G, Nalá R, Casmo V, Sabonete A, Mapaco L, Monteiro
J.  Geographic distribution and prevalence of schistosomiasis
and soil-transmitted helminths among school children in
Mozambique. Am J Trop Med Hyg. 2009;81 Suppl. 5:799–803.
9. Nkengazong L, Njiokou F, Asonganyi T. Two years impact of
single praziquantel treatment on urinary schistosomiasis in
the Barombi Kotto focus, South West Cameroon. J Parasit
Vector Biol. 2013;5:83–9.
0. Müller I, Coulibaly JT, Fürst T, et al. Effect of schistosomiasis
and  soil-transmitted helminth infections on physical ﬁtness
of  school children in Côte d’Ivoire. PLoS Neglect Trop Dis.
2011;5:e1239.
1. Rollinson D, Knopp S, Levitz S, et al. Time to set agenda for
schistosomiasis elimination. Acta Trop. 2013;128:423–40.
2. Hürlimann E, Yapi RB, Houngbedji CA, et al. The epidemiology
of polyparasitism and implications for morbidity in two rural
communities of Côte d’Ivoire. Parasit Vectors. 2014;7:81.
3. Prual A, Daouda H, Develoux M, Sellin B, Galan P, Hercberg S.
Consequences of Schistosoma haematobium infection on the
iron status of schoolchildren in Niger. Am J Trop Med  Hyg.
1992;47:291–7.
4. Koukounari A, Gabrielli AF, Touré S, et al. Schistosoma
haematobium infection and morbidity before and after
large-scale administration of praziquantel in Burkina Faso. J
Infect Dis. 2007;196:659–69.
5. Mbabazi PS, Andan O, Fitzgerald DW, Chitsulo L, Engels D,
Downs JA. Examining the relationship between urogenital
schistosomiasis and HIV infection. PLoS Negl Trop Dis.
2011;5:e1396.
 2 0 1 
3
3
3
3
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
5
5
5
5
6
6
6
6
6
6
6
6
6
6
7b r a z j i n f e c t d i s .
6. Kjetland EF, Ndhlovu PD, Gomo E, et al. Association between
genital schistosomiasis and HIV in rural Zimbabwean
women. AIDS. 2006;20:593–600.
7. Friedman JF, Mital P, Kanzaria HK, Olds OR, Kurtis JD.
Schistosomiasis and pregnancy. Trends Parasitol.
2007;23:159–64.
8. Ajanga A, Lwambo NJ, Blair L, Nyandindi U, Fenwick A,
Brooker S. Schistosoma mansoni in pregnancy and associations
with anaemia in northwest Tanzania. Trans R Soc Trop Med
Hyg. 2006;100:59–63.
9. Dreyfuss ML, Msamanga GI, Spiegelman D, et al.
Determinants of low birth weight among HIV-infected
pregnant women in Tanzania. Am J Clin Nutr. 2001;74:814–26.
0. El-Awady MK, Youssef SS, Omran  MH, Tabil AA, El Garf WT,
Salem AM. Soluble egg antigen of Schistosoma haematobium
induces HCV replication in PBMC from patients with chronic
HCV infection. BMC Infect Dis. 2006;6:91.
1. Mas-Coma S, Valero MA, Bargues MD. Climate change effects
on  trematodiases, with emphasis on zoonotic fascioliasis and
schistosomiasis. Vet Parasitol. 2009;163:264–80.
2. Ernould JC, Ba K, Sellin B. The impact of the local water
development programme on the abundance of the
intermediate hosts of schistosomiasis in three villages of the
Senegal River delta. Ann Trop Med Parasit. 1999;93:135–45.
3. Brooker S. Spatial epidemiology of human schistosomiasis in
Africa: risk models, transmission dynamics and control.
Trans R Soc Trop Med Hyg. 2007;101:1–8.
4. Kapito-Tembo AP, Mwapasa V, Meshnick SR, et al. Prevalence
distribution and risk factors for Schistosoma hematobium
infection among school children in Blantyre, Malawi. PLoS
Neglect Trop Dis. 2009;3:e361.
5. Clennon JA, Mungai PL, Muchiri EM, King CH, Kitron U. Spatial
and temporal variations in local transmission of Schistosoma
haematobium in Msambweni, Kenya. Am J Trop Med Hyg.
2006;75:1034–41.
6. Fenwick A, Webster JP, Bosque-Oliva E, et al. The
schistosomiasis control initiative (SCI): rationale,
development and implementation from 2002 to 2008.
Parasitology. 2009;136:1719–30.
7. Ugbomoiko US, Ofoezie IE, Okoye IC, Heukelbach J. Factors
associated with urinary schistosomiasis in two peri-urban
communities in south-western Nigeria. Ann Trop Med
Parasitol. 2010;104:409–19.
8. Esrey SA, Potash JB, Roberts L, Shiff C. Effects of improved
water supply and sanitation on ascariasis, diarrhoea,
dracunculiasis, hookworm infection, schistosomiasis, and
trachoma. Bull World Health Organ. 1991;69:609.
9. Kanwai S, Ndams IS, Kogi E, Abdulkadir JS, Gyam ZG,
Bechemagbor A. Cofactors inﬂuencing prevalence and
intensity of Schistosoma haematobium infection in sedentary
Fulani settlements of Dumbi, Igabi LGA, Kaduna State,
Nigeria. Sci World J. 2011;6:15–9.
0. Fenwick A, Webster JP. Schistosomiasis: challenges for
control, treatment and drug resistance. Curr Opin Infect Dis.
2006;19:577–82.
1. Doenhoff MJ, Hagan P, Cioli D, et al. Praziquantel: its use in
control of schistosomiasis in sub Saharan Africa and current
research needs. Parasitology. 2009;136:1825–35.
2. El-Ridi AF, Tallima HA. Novel therapeutic and prevention
approaches for schistosomiasis: review. J Adv Res.
2013;4:467–78.
3. World Health Organization. WHO schistosomiasis: progress
report 2001–2011 and strategic plan 2012–2020; 2013. Available
75;1 9(2):196–205 205
from: http://www.who.int/neglected disease/en [accessed
15.04.14].
4. Doenhoff MJ, Cioli D, Utzinger J. Praziquantel: mechanism of
action, resistance and new derivatives for schistosomiasis.
Curr Opin Infect Dis. 2008;21:659–67.
5. Mostafa MH, Helmi S, Badawi AF, Tricker AR, Spiegelhalder B,
Preussmann R. Nitrate, nitrite and volatile N-nitroso
compounds in the urine of Schistosoma haematobium and
Schistosoma mansoni infected patients. Carcinogenesis.
1994;15:619–25.
6. Samaras V, Rafailidis PI, Mourtzoukou EG, Peppas G, Falagas
ME. Chronic bacterial and parasitic infections and cancer: a
review. J Infect Dev Ctries. 2010;4:267–81.
7. Zaghloul MS. Bladder cancer and schistosomiasis. J Egypt Natl
Cancer Inst. 2012;24:151–9.
8. Groeneveld AE, Marszalek WW,  Heyns CF. Bladder cancer in
various population groups in the greater Durban area of
KwaZulu-Natal: South Africa. Br J Urol. 1996;78:205–8.
9. van der Werf MJ, de Vlas SJ, Brooker S, et al. Quantiﬁcation of
clinical morbidity associated with schistosome infection in
sub-Saharan Africa. Acta Trop. 2003;86:125–39.
0. Gray DJ, McManus DP, Li Y, Williams GM, Bergquist R, Ross AG.
Schistosomiasis elimination: lessons from the past guide the
future. Lancet Infect Dis. 2010;10:733–6.
1. Bergquist R, Utzinger J, McManus DP. Trick or treat: the role of
vaccines in integrated schistosomiasis control. PLoS Neglect
Trop Dis. 2008;2:e244.
2. Hotez PJ, Fenwick A. Schistosomiasis in Africa: an emerging
tragedy in our new global health decade. PLoS Neglect Trop
Dis. 2009;3:e485.
3. Geddes AA. The history of smallpox. Clin Dermatol.
2006;24:152–7.
4. Beaumier CM, Gillespie PM, Hotez PJ, Bottazzi ME. New
vaccines for neglected parasitic diseases and dengue. Transl
Res. 2013;162:144–55.
5. Knopp S, Person B, Ame SM, et al. Elimination of
schistosomiasis transmission in Zanzibar: baseline ﬁndings
before the onset of a randomized intervention trial. PLoS Negl
Trop Dis. 2013;7:e2474.
6. Campbell SJ, Savage GB, Gray DJ, et al. Water, sanitation,
hygiene (WASH): a critical component for sustainable
soil-transmitted helminth and schistosomiasis control. PLoS
Negl Trop Dis. 2014;8:2651.
7. Stothard JR, Mook P, Mgeni AF, Khamis IS, Khamis AN,
Rollinson D. Control of urinary schistosomiasis on Zanzibar
(Unguja Island): a pilot evaluation of the educational impact
of the Juma na Kichocho health booklet within primary
schools. Mem Inst Oswaldo Cruz. 2006;101:119–24.
8. Siddiqui AA, Phillips T, Charest H, et al. Enhancement of
Smp-80 (large subunit of calpain) induced protective
immunity against Schistosoma mansoni through co-delivery of
interleukin-2 and interleukin-12 in a DNA vaccine
formulation. Vaccine. 2003;21:2882–9.
9. Da’dara AA, Li YS, Xiong T, et al. DNA-based vaccines protect
against zoonotic schistosomiasis in water buffalo. Vaccine.
2008;26:3617–25.
0. Pearson MS, Pickering DA, McSorley HJ, et al. Enhanced
protective efﬁcacy of a chimeric form of the schistosomiasis
vaccine antigen Sm-TSP-2. PLoS Neglect Trop Dis.
2012;6:e1564.
1. Oyinloye B, Adenowo F, Gxaba N, Kappo A. The promise of
antimicrobial peptides for treatment of human
schistosomiasis. Curr Drug Targets. 2014;15:852–9.
